Dr. Puvvada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Duke University Medical Ctr
Division of Medical Oncology 441 Sealy G Mudd Building
Durham, NC 27710Phone+1 919-684-2287
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
University of North Carolina HospitalsResidency, Internal Medicine, 2006 - 2009
University of South Florida College of MedicineClass of 2006
Certifications & Licensure
NC State Medical License 2009 - 2025
AZ State Medical License 2012 - 2019
Clinical Trials
- Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL Start of enrollment: 2012 Aug 31
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 05
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Publications & Presentations
PubMed
- 1316 citationsTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada
The New England Journal of Medicine. 2016-01-27 - 101 citationsEfficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, Do-Youn Oh, Susana Banerjee
Journal of Clinical Oncology. 2024-01-01 - 65 citationsNF-κB and Bcl-3 Activation Are Prognostic in Metastatic Colorectal CancerSoham D. Puvvada, William K. Funkhouser, Kevin G. Greene, Allison M. Deal, Haitao Chu
Oncology. 2010-01-01
Journal Articles
- Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell LymphomaDaniel Persky, Soham Puvvada, Catherine Spier, Gregory Monohan, Ari VanderWalde, Daruka Mahadevan, Clinical Cancer Research
Press Mentions
VCR Regimen Showed Efficacy in Mantle Cell and Indolent LymphomasOctober 6th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
